MTL-CEBPA

DRUG4 trials

Sponsors

Mina Alpha Limited, National University Hospital, Singapore

Conditions

Advanced Hepatocellular CarcinomaHepatitis BHepatitis CHepatocellular CarcinomaLiver CancerSolid Tumor, Adult

Phase 1

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

Mina Alpha LimitedHepatocellular Carcinoma, Liver Cancer

Start: 2016-03-01End: 2025-07-31Updated: 2025-03-10

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)

CompletedNCT04105335

Mina Alpha LimitedSolid Tumor, Adult

Start: 2019-11-13End: 2025-01-25Updated: 2025-03-06

Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Active, not recruitingNCT05097911

National University Hospital, SingaporeAdvanced Hepatocellular Carcinoma

Start: 2021-08-02End: 2027-04-30Target: 33Updated: 2025-09-23

Phase 2

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

CompletedNCT04710641

Mina Alpha LimitedHepatitis B, Hepatitis C, Hepatocellular Carcinoma

Start: 2022-01-01End: 2025-01-25Updated: 2025-03-06

Related Papers

The small activating RNA AW1-51 induces locus-specific demethylation and CEBPA protein early upregulation

Blood2025-11-03

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

2025-03-315 citations

Small Activating RNA-Mediated Induction of <i>HBG</i> Via Liposome Delivery for <i>In Vivo</i> Treatment of Sickle Cell Disease and Beta-Thalassemia

Blood2024-11-051 citations

515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours

Regular and Young Investigator Award Abstracts2021-11-011 citations

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

Clinical Cancer Research2021-08-1883 citations

Abstract 1730: Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients

Cancer Research2021-07-012 citations

Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2020-05-203 citations

First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2020-02-013 citations

Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Journal of Clinical Oncology2018-05-206 citations

Abstract 1508: MTL-CEBPA activates the transcription factor CEBPalpha leading to inhibition of hepatocellular cancer growth

Cancer Research2017-07-01

First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Journal of Clinical Oncology2017-05-205 citations